20-F: Mobile-health Network Solutions Reports Fiscal Year 2024 Results

Mobile-health Network Solutions reports a 77.4% increase in revenue for fiscal year 2024, driven by growth in telemedicine services, but incurs a net loss due to increased operating expenses and share-based compensation.

Summary

• Mobile-health Network Solutions (MNDR) reported its financial results for the fiscal year ended June 30, 2024.
• The company experienced a significant revenue increase of 77.4%, reaching $13.9 million compared to $7.9 million in the previous fiscal year.
• This growth was primarily driven by an increase in telemedicine revenue, particularly from the private sector, and a smaller contribution from the sale of medicine and medical devices.
• Despite the revenue growth, the company reported a net loss of $15.6 million, a substantial increase from the $3.2 million loss in the prior year.
• The increased loss was attributed to higher operating expenses, including salaries, administrative costs, and significant share-based compensation expenses.
• The company's adjusted EBITDA, a non-GAAP measure, showed a loss of $3.37 million compared to a loss of $2.32 million in the previous year.
• The company's cash and cash equivalents stood at $6.7 million as of June 30, 2024.
• The company is facing a temporary suspension of teleconsultation services at one of its clinics, which is expected to impact teleconsultation case numbers.
• The company is implementing a clawback policy to recoup incentive compensation from executives in the event of financial restatements.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While revenue growth is positive, the significant net loss and increased operating expenses raise concerns. The temporary suspension of teleconsultation services adds further uncertainty.

Positives

• Significant revenue growth of 77.4% indicates strong market demand for the company's services.
• Successful completion of IPO provides additional capital for growth and operations.
• The company has a large and growing user base on its MaNaDr platform.
• The company is expanding its service offerings and technological capabilities, including AI integration.
• The company has a strong management team with experience in both technology and healthcare.

Negatives

• Substantial net loss of $15.6 million raises concerns about profitability.
• Significant increase in operating expenses, including share-based compensation, is impacting the bottom line.
• Temporary suspension of teleconsultation services at one clinic poses a challenge to financial performance.
• The company is facing increasing competition in the telehealth solutions market.
• The company is subject to extensive and evolving regulatory requirements.

Risks

• Maintaining user trust is critical, and any failure to do so could damage the company's reputation.
• The company may not be able to manage the growth of its business and operations effectively.
• The company's healthcare solutions may not drive user engagement or provide a superior user experience.
• The company may not be able to develop its existing technology infrastructure or recoup investments.
• The company's self-developed technologies may contain undetected errors or may not operate properly.
• The company's failure in ensuring safety and compliance of Generative AI.
• The company may be subject to fines or other penalties under the Healthcare Services Act.
• The company may not be able to detect or prevent fraud or other misconduct committed by employees or third parties.
• The company may need additional capital but may not be able to obtain such on favorable terms or at all.
• The company is subject to credit risk with respect to trade receivables.
• The company faces risks relating to the political, economic, regulatory, social and legal environments in the jurisdictions in which it operates.
• COVID-19 or any other infectious and communicable diseases, as well as the occurrence of any acts of God, war, terrorist attacks and other catastrophic events may have a material adverse effect on the company's business, financial condition, results of operations and prospects.
• Fluctuations in exchange rates could have a material and adverse effect on the company's results of operations.

Future Outlook

The company plans to expand its user base, enhance user engagement through technological tools, expand service and product offerings, and seek merger and acquisition opportunities.

Industry Context

The telehealth solutions industry is rapidly growing, driven by technological advancements and increasing demand for convenient healthcare services. The company is positioning itself to capitalize on this growth by expanding its service offerings and geographic reach.

Comparison to Industry Standards

• The document states that, according to Frost & Sullivan, MaNaDr is a leading telehealth solutions provider in Singapore in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application.
• The document states that, according to Frost & Sullivan, MaNaDr is amongst the fastest-growing telehealth solutions providers in Singapore.
• The document states that, according to Frost & Sullivan, MaNaDr is the only telehealth solutions company based in Singapore that provides integrated smart health-tech service in the APAC region.
• The document states that, according to Frost & Sullivan, MaNaDr has set up one of the smartest 24/7 virtual care ecosystems and support groups to help users navigate the complexities faced in receiving correct and timely care.
• The document states that, according to Frost & Sullivan, MaNaDr operates Singapores only in-app live group chat service via MaNaChat, the 24/7 customer support service, and has one of the fastest response times in Singapore and globally to support users, and hosts the regions only in-app drug support and discussion group via MaNaForum, where users can organize bulk purchases of drugs, discuss matters relating to the purchase of drugs, as well as the uses, side effects, and latest news on drugs.
• The document states that, according to Frost & Sullivan, MaNaDr is a pioneer in the APAC region, spearheading the building of a comprehensive weight management ecosystem that aims to target over 60% of users on our MaNaDr platform who access the Consult Weight Management function on our MaNaDr platform and who are overweight.

Management Changes

Corporate Governance

Legal Proceedings

• The Ministry of Health (MOH) has directed Manadr Clinic @Citygate to temporarily suspend the provision of outpatient medical services via teleconsultation, effective from August 16, 2024.

Related Party Transactions

• The company has ongoing transactions with related parties, including clinics owned by directors, for the provision of services and purchase of goods.
• The company obtains advances from its directors or shareholders for working capital purposes.

Stakeholder Impact

• Shareholders: The net loss and increased operating expenses may negatively impact shareholder value.
• Employees: The company's performance may affect employee compensation and job security.
• Customers: The temporary suspension of teleconsultation services at one clinic may disrupt service availability for some customers.
• Suppliers: The company's financial performance may impact its ability to meet its obligations to suppliers.

Next Steps

• Expand user base and enhance user engagement.
• Expand service and product offerings to cover the healthcare value chain.
• Seek merger and acquisition opportunities and partnerships to add scale and diversify the business.

Key Dates

Keywords

telehealth, healthcare, MaNaDr, revenue, net loss, financial results, operating expenses, share-based compensation, IPO, Singapore